After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Regeneron has moved closer to a regulatory filing for its BCMAxCD3 bispecific antibody linvoseltamab, the first of a series of bispecifics that is spearheading its oncology pipeline. New data from ...